Navigation Links
Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
Date:9/3/2009

JERUSALEM, September 3 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTC BB: ORMP.OB) (http://www.oramed.com), a developer of alternative drug delivery systems, announced today that Nadav Kidron, its Chief Executive Officer, is scheduled to present at the Rodman & Renshaw's 11th Annual Healthcare Conference on Friday September 11, 2009 at 10:00 a.m. EDT. The conference will be held at the New York Palace Hotel in New York City.

Nadav Kidron is scheduled to speak in the Fahnestock Salon on the fifth floor of the hotel. He will discuss Oramed's strategic initiatives, updates and product pipeline.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com.

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, tim
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
2. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
3. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
4. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
5. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
6. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
7. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... and TEL AVIV, Israel , ... or the "Company") (NYSE MKT: NSPR), a leader in embolic ... the Company,s President and Chief Executive Officer, and ... participate in the Benchmark Company, LLC One-on-One Investor Conference on ... Wisconsin Ave., Milwaukee, WI. ...
(Date:5/24/2013)... Senomyx , Inc. (NASDAQ: ... to discover, develop, and commercialize novel flavor ingredients, announced ... the Company,s Vice President, Biology and Gwen ... Communications, will present an overview of Senomyx,s technology and ... Time (7:25 a.m. Pacific Time) during the Citi 2013 ...
(Date:5/24/2013)... 24, 2013 This market report ... kinase profiling carried out in May 2013. The ... breakdown of the responses for each question, its ... It also highlights some interesting differences, particularly between ... bottom-up models were developed to estimate the in ...
(Date:5/24/2013)... May 24, 2013 Many factors impact ... uptake or efflux transporters at the blood-tissue barrier. Even ... to unbound fractions in the tissue rather than the ... disposition challenges is required to guide lead optimization, predict ... any species-dependent variables that may impact the likely human ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 3Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2
... BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the ... results for the first quarter of 2009. DOR,s revenues ... million compared to $0.7 million for the first quarter ... to decreased research and development amounts drawn down from ...
... - Investigating the Real Burden ... Pressure Goal and SHARE(ing) the Knowledge,( http://www.SHARE-hypertension.com ) ... committee announce the launch of Supporting,Hypertension Awareness & ... (17th May). SHARE is a collaborative program of ...
... the Georgia Institute of Technology and the National ... measured the unusual energy spectrum of graphene, a ... tantalized and puzzled scientists since its discovery in ... Science ,* their work adds new detail ...
Cached Biology Technology:DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 5SHARE Program Launched to Address the Challenges of Achieving Blood Pressure Goal 2SHARE Program Launched to Address the Challenges of Achieving Blood Pressure Goal 3SHARE Program Launched to Address the Challenges of Achieving Blood Pressure Goal 4SHARE Program Launched to Address the Challenges of Achieving Blood Pressure Goal 5Graphene yields secrets to its extraordinary properties 2
(Date:5/24/2013)... scientists from around the world today issued a stark ... of one or two generations, the majority of the ... the handicap of severe pressure on fresh water, an ... substitute. This handicap will be self-inflicted and is, we ... chronic underlying problems led by mismanagement and sent a ...
(Date:5/23/2013)... Science , Automated conserved noncoding ... promoter evolution among grasses , Within the genome ... DNA that undergo little change in position and sequence ... any proteins. Some of these evolutionarily stable sequences, so-called ... expression of other genes or the condensation of chromosomes, ...
(Date:5/23/2013)... world,s most popular fruit, can be made both better-tasting ... varieties. , "Working with GM tomatoes that are ... a specific compound, allows us to pinpoint exactly how ... from the John Innes Centre. , The research could ... and shelf life characteristics because even higher levels of ...
Breaking Biology News(10 mins):A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3The world's favorite fruit only better-tasting and longer-lasting 2
... the structure and function of cells and the process ... ends constantly elongate and retreat in a thrashing frenzy ... Medusa's hair. Known prosaically as "dynamic instability," this ongoing ... workings of microtubules in the cell. , For the ...
... requires treatment of the sexual partners of infected patients. ... antibiotics to give their partners is more effective than ... to an article in the Sept. 1 issue of ... or gonorrhea were more likely to see and talk ...
... can burrow into a tumor, seal the exits and ... leaving healthy cells unscathed. , MIT researchers have designed ... double-acting, drug-packing "nanocell" proved effective and safe, with prolonged ... lung cancer--in mice. , The work will be reported ...
Cached Biology News:The making and breaking of microtubules 2The making and breaking of microtubules 3The making and breaking of microtubules 4The making and breaking of microtubules 5Measurement Challenges In Detecting Cancer Biomarkers 2Measurement Challenges In Detecting Cancer Biomarkers 3MIT engineers an anti-cancer smart bomb 2
... BioLogic Maximizer kit, 110 to 220 ... monitoring and doubles flow rates and ... systems. The kit includes the Maximizer ... starter kit, tubing kit, system cable ...
... antifade reagent is used to ... standard fluorescence microscopy. The unique ... a wide variety of fixed ... fluorescein, rhodamine, sulforhodamine 101, coumarin, ...
... Signets FAST RED Chromogen System consists ... FAST RED reacts in the presence of ... minimal background noise. The FAST RED ... ,The System Contains: , , Vial ...
... Dodeca silver stain kits are optimized ... including Bio-Rad Dodeca stainers. This silver ... of proteins in polyacrylamide gels and ... includes sensitizer concentrate, silver reagent concentrate, ...
Biology Products: